Cognition Therapeutics Statistics
Total Valuation
CGTX has a market cap or net worth of $85.99 million. The enterprise value is $55.32 million.
| Market Cap | 85.99M |
| Enterprise Value | 55.32M |
Important Dates
The next estimated earnings date is Thursday, August 6, 2026, before market open.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CGTX has 89.50 million shares outstanding. The number of shares has increased by 70.27% in one year.
| Current Share Class | 89.50M |
| Shares Outstanding | 89.50M |
| Shares Change (YoY) | +70.27% |
| Shares Change (QoQ) | +0.66% |
| Owned by Insiders (%) | 1.87% |
| Owned by Institutions (%) | 18.80% |
| Float | 81.83M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.87 |
| P/TBV Ratio | 2.87 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.92, with a Debt / Equity ratio of 0.02.
| Current Ratio | 5.92 |
| Quick Ratio | 5.75 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3,295.46 |
Financial Efficiency
Return on equity (ROE) is -92.82% and return on invested capital (ROIC) is -123.73%.
| Return on Equity (ROE) | -92.82% |
| Return on Assets (ROA) | -89.79% |
| Return on Invested Capital (ROIC) | -123.73% |
| Return on Capital Employed (ROCE) | -142.39% |
| Weighted Average Cost of Capital (WACC) | 13.83% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.40M |
| Employee Count | 14 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +55.82% in the last 52 weeks. The beta is 1.75, so CGTX's price volatility has been higher than the market average.
| Beta (5Y) | 1.75 |
| 52-Week Price Change | +55.82% |
| 50-Day Moving Average | 1.19 |
| 200-Day Moving Average | 1.31 |
| Relative Strength Index (RSI) | 38.76 |
| Average Volume (20 Days) | 2,505,541 |
Short Selling Information
The latest short interest is 7.07 million, so 7.90% of the outstanding shares have been sold short.
| Short Interest | 7.07M |
| Short Previous Month | 7.51M |
| Short % of Shares Out | 7.90% |
| Short % of Float | 8.64% |
| Short Ratio (days to cover) | 3.19 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -42.84M |
| Pretax Income | -19.58M |
| Net Income | -19.58M |
| EBITDA | -42.82M |
| EBIT | -42.84M |
| Earnings Per Share (EPS) | -$0.25 |
Balance Sheet
The company has $31.13 million in cash and $465,000 in debt, with a net cash position of $30.67 million or $0.34 per share.
| Cash & Cash Equivalents | 31.13M |
| Total Debt | 465,000 |
| Net Cash | 30.67M |
| Net Cash Per Share | $0.34 |
| Equity (Book Value) | 29.91M |
| Book Value Per Share | 0.33 |
| Working Capital | 29.76M |
Cash Flow
| Operating Cash Flow | -20.25M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 20,250 |
| Net Borrowing | -348,000 |
| Free Cash Flow | -20.25M |
| FCF Per Share | -$0.23 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CGTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -70.27% |
| Shareholder Yield | -70.27% |
| Earnings Yield | -22.77% |
| FCF Yield | -23.55% |
Analyst Forecast
The average price target for CGTX is $3.50, which is 264.28% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $3.50 |
| Price Target Difference | 264.28% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |